Olema Pharmaceuticals, Inc. (OLMA)
10.27
-0.52
(-4.82%)
USD |
NASDAQ |
Aug 28, 16:00
10.27
0.00 (0.00%)
After-Hours: 20:00
Olema Pharmaceuticals Enterprise Value : 440.72M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 440.72M |
| August 27, 2026 | 486.20M |
| August 26, 2026 | 491.45M |
| August 25, 2026 | 496.69M |
| August 24, 2026 | 454.72M |
| August 21, 2026 | 477.45M |
| August 20, 2026 | 495.82M |
| August 19, 2026 | 531.67M |
| August 18, 2026 | 473.96M |
| August 17, 2026 | 484.45M |
| August 14, 2026 | 472.21M |
| August 13, 2026 | 461.71M |
| August 12, 2026 | 455.59M |
| August 11, 2026 | 454.72M |
| August 10, 2026 | 586.77M |
| August 07, 2026 | 596.39M |
| August 06, 2026 | 574.53M |
| August 05, 2026 | 555.29M |
| August 04, 2026 | 571.03M |
| August 03, 2026 | 529.05M |
| July 31, 2026 | 543.92M |
| July 30, 2026 | 576.28M |
| July 29, 2026 | 521.18M |
| July 28, 2026 | 558.78M |
| July 27, 2026 | 592.89M |
| Date | Value |
|---|---|
| July 24, 2026 | 565.78M |
| July 23, 2026 | 569.28M |
| July 22, 2026 | 547.42M |
| July 21, 2026 | 556.16M |
| July 20, 2026 | 535.17M |
| July 17, 2026 | 545.67M |
| July 16, 2026 | 510.69M |
| July 15, 2026 | 576.28M |
| July 14, 2026 | 578.90M |
| July 13, 2026 | 578.90M |
| July 10, 2026 | 584.15M |
| July 09, 2026 | 616.50M |
| July 08, 2026 | 615.63M |
| July 07, 2026 | 647.11M |
| July 06, 2026 | 659.35M |
| July 02, 2026 | 647.99M |
| July 01, 2026 | 599.01M |
| June 30, 2026 | 636.62M |
| June 29, 2026 | 564.07M |
| June 26, 2026 | 493.33M |
| June 25, 2026 | 496.83M |
| June 24, 2026 | 471.50M |
| June 23, 2026 | 418.23M |
| June 22, 2026 | 371.94M |
| June 18, 2026 | 329.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.128B |
| Alnylam Pharmaceuticals, Inc. | 31.39B |
| Anika Therapeutics, Inc. | 269.22M |
| Savara, Inc. | 937.77M |
| Vericel Corp. | 2.028B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -63.20M |
| Total Expenses (Quarterly) | 63.20M |
| EPS Diluted (Quarterly) | -0.605 |
| Earnings Yield | -20.63% |
| Normalized Earnings Yield | -20.63 |